Oxford Nanopore Technologies received a 'buy' rating upgrade from Panmure Liberum, with its target price increased to 196p from 170p. The upgrade follows a strategic pivot towards the high-value biopharma market, backed by a $20 million upfront payment and $15 million in product commitments from a new global diagnostics licensing deal. This deal helps reduce near-term losses and supports cash flow goals, despite some revenue estimate cuts. The company aims to break even by 2028, but success depends on strong adoption by biopharma customers moving from validation to commercial use.
Peter Schiff argues that artificial intelligence (AI) is a threat to Bitcoin rather than a benefit, competing for speculative capital, electricity, and infrastructure. He suggests AI could potentially uncover vulnerabilities in Bitcoin's code, though...
Ondas reported a remarkable second quarter with revenue increasing over thirteen times compared to the previous year and a pro forma backlog reaching $757 million. The company benefits from significant defense contracts, involvement in a major U.S. d...
After a bullish week adding over $480 billion to crypto market cap, Bitcoin led inflows but dipped slightly at August's end. Hyperliquid (HYPE) reached a new all-time high and entered price discovery, showing strong momentum with a 3% pullback that c...
Spartan Metals has begun a 3,000-meter diamond core drilling program at its 100% owned Eagle Tungsten-Silver-Rubidium Project in Nevada. This drilling targets three key areas to assess tungsten and associated minerals, aiming to advance domestic supp...
Bitcoin's price surged about 22% from the mid-$63,000s to nearly $79,000 before consolidating, driven by strong spot demand and a major short squeeze. Despite the price rally, coin-denominated open interest fell 11%, indicating leverage did not incre...
